A Systems Approach to Accelerating the Pharmaceutical Industry Pipeline
Presented by Pfizer and Rosa at 6th International Symposium on Measurement & Kinetics of In Vivo Drug Effects, 2010
Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma.
Presented by MediciNova and Rosa at American College of Chest Physicians Annual Meeting (CHEST), 2010
PK/PD Modeling of MN-221 for COPD and Acute Asthma
Presented by MediciNova and Rosa at Cambridge Health Institute (CHI) Discovery on Target (DOT): COPD, 2010
MN‑221, a Novel Beta2-Adrenergic Agonist for Treatment of Acute Asthma and COPD
Presented by MediciNova and Rosa at Cambridge Health Institute (CHI) Discovery on Target (DOT): COPD, 2010
Modeling Glucose Metabolism in Diabetes
Presented by Pfizer and Rosa at Cambridge Healthtech Institute, Discovery on Target (CHI-DOT): Diabetes, 2010
Modeling an antibody therapeutic
Presented by Rosa at the Quantitative & Systems Pharmacology Workshop II, National Institute of General Medical Sciences (NIGMS), 2010
Systems Approaches to Modeling Diabetes within Pfizer With Applications to SGLT2i and Modeling Glucose Metabolism in Diabetes
Presented by Pfizer and Rosa at Cambridge Healthtech Institute (CHI) Discovery on Target (DOT), 2010
